ArticleCells2023
HDL-Associated Proteins in Subjects with Polycystic Ovary Syndrome: A Proteomic Study.
Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- Lipid Challenge Reveals Amplified Apolipoprotein Responses with Preserved Temporal Pattern in Polyendocrine Metabolic Ovarian Syndrome: An Exploratory Study.International journal of molecular sciences · 2026Trial
- Association of HDL-cholesterol related inflammatory ratios with reproductive outcomes in women with polycystic ovary syndrome undergoing frozen-thawed embryo transfer.Journal of ovarian research · 2026Article
- HDL proteome: from its characterization to quantitative measurements in particle subspecies and functional associations.Expert review of proteomics · 2025Review
- The Role of the Liver in the Pathophysiology of PCOS: A Literature Review.Biomolecules · 2025Review
- The effects of trace element supplementation on glycolipid metabolism in PCOS: a systematic review and meta-analysis.Frontiers in nutrition · 2025Article
- Triglyceride-glucose index and lipid ratios in women with and without polycystic ovary syndrome: a systematic review and meta-analysis.Therapeutic advances in endocrinology and metabolism · 2025Article
- Polycystic Ovary Syndrome and Ferroptosis: Following Ariadne's Thread.Biomedicines · 2024Article
- A Cross-Sectional Study of Alzheimer-Related Proteins in Women with Polycystic Ovary Syndrome.International journal of molecular sciences · 2024Article
- Association Between Female Androgen Levels, Metabolic Syndrome, and Cardiovascular Disease: An NHANES Analysis (2013-2016).International journal of women's health · 2024Article
- Hepatokines: the missing link in the development of insulin resistance and hyperandrogenism in PCOS?Hormones (Athens, Greece) · 2023Review
- A study on the immunological vitality of an inflammatory biomarker explored with rs5743708 polymorphism inSaudi journal of biological sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSerum lipoproteins, with the exception of high-density lipoprotein cholesterol (HDL-C), are increased in polycystic ovary syndrome (PCOS) and their levels may reflect the associated obesity and insulin resistance, but the nature of this association is not fully explained. Therefore, proteomic analysis of key proteins in lipoprotein metabolism was performed.
methodsIn this cohort study, plasma was collected from 234 women (137 with PCOS and 97 controls without PCOS). Somalogic proteomic analysis was undertaken for the following 19 proteins involved in lipoprotein, and particularly HDL, metabolism: alpha-1-antichymotrypsin; alpha-1-antitrypsin; apolipoproteins A-1, B, D, E, E2, E3, E4, L1, and M; clusterin; complement C3; hemopexin; heparin cofactor II; kininogen-1; serum amyloid A-1; amyloid beta A-4; and paraoxonase-1.
resultsThe levels of apolipoprotein E were higher in PCOS (
conclusionsThese data contribute to the concern of the deleterious dyslipidemia found in PCOS, with the novel combination reported here of higher levels of ApoE, C3 and HCFII together with lower ApoM. The dysregulation of these proteins could circumvent the protective effect of HDL-C and contribute to a more atherogenic profile that may increase cardiovascular risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.